Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.70 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14493967 | 1.00 | AR (0.70) | ARSRD5A2KCNH2 | |
| SCHEMBL4458128 | 1.00 | AR (0.70) | ARSRD5A2KCNH2 | |
| SCHEMBL13465160 | 1.00 | AR (0.70) | ARSRD5A2KCNH2 | |
| SCHEMBL8410044 | 1.00 | AR (0.70) | ARSRD5A2KCNH2 | |
| SCHEMBL7624008 | 1.00 | AR (0.70) | ARSRD5A2KCNH2 | |
| SCHEMBL5242813 | 0.89 | AR (0.55) | ARSRD5A2KCNH2 | |
| SCHEMBL5341211 | 0.89 | AR (0.55) | ARSRD5A2KCNH2 | |
| SCHEMBL797639 | 0.89 | AR (0.54) | ARSRD5A2KCNH2 | |
| SCHEMBL5874196 | 0.88 | AR (0.74) | ARSRD5A2KCNH2 | |
| SCHEMBL5116733 | 0.88 | AR (0.74) | ARSRD5A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5138063-A | Testosterone reductase inhibitors | MERCK & CO., INC. (US) | 1992-08-11 | — | — | US | claimed |
| EP-0271219-B1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING 17-BETA-METHOXYCARBONYL-4-METHYL-4-AZA-5-ALPHA-ANDROST-1-EN-3-ONE | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |
| EP-0271219-A1 | Topical pharmaceutical composition containing 17-beta-methoxycarbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one | MERCK & CO. INC. (US) | 1988-06-15 | — | — | EP | claimed |
| EP-1960417-B1 | POLYMORPHS OF ANDROGEN RECEPTOR MODULATOR - (N-3H-IMIDAZO [4 , 5-B] PYRIDIN-2-YL-METHYL) -2-FLUORO-4-METHYL-3-OXO-4-AZA-ANDROST- 1-EN-17 . BETA . -CARBOXAMIDE | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20090048283-A1 | Salt of an androgen receptor modulator | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| EP-1960417-A1 | POLYMORPHS OF ANDROGEN RECEPTOR MODULATOR - (N-3H-IMIDAZO [4 , 5-B] PYRIDIN-2-YL-METHYL) -2-FLUORO-4-METHYL-3-OXO-4-AZA-ANDROST- 1-EN-17 . BETA . -CARBOXAMIDE | Merck & Co., Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-7365202-B2 | Polymorphs of an androgen receptor modulator | MERCK & CO., INC. (US) | 2008-04-29 | — | — | US | disclosed |
| WO-2007067490-A1 | POLYMORPHS OF ANDROGEN RECEPTOR MODULATOR - (N-3H-IMIDAZO [4 , 5-B] PYRIDIN-2-YL-METHYL) -2-FLUORO-4-METHYL-3-OXO-4-AZA-ANDROST- l-EN-17 . BETA . -CARBOXAMIDE | MERCK & CO., INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129548-A1 | Polymorphs of an androgen receptor modulator | MERCK SHARP & DOHME CORP. | 2007-06-07 | — | — | US | disclosed |
| US-RE39056-E1 | 4-Azasteroids for treatment of hyperandrogenic conditions | MERCK & CO, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-6432971-B2 | Method of prevention of prostatic carcinoma with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
| EP-0314199-B1 | 17 BETA-SUBSTITUTED-4-AZA-5 ALPHA-ANDROSTENONES AND THEIR USE AS 5 ALPHA-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1991-09-18 | — | — | EP | disclosed |
| US-4888336-A | DECREASE DIHYDROTESTOSTERONE ACTIVITY | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-19 | — | — | US | disclosed |
| EP-0314199-A1 | 17 Beta-substituted-4-aza-5 alpha-androstenones and their use as 5 alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1989-05-03 | — | — | EP | disclosed |
| EP-0285383-A2 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0277002-A2 | Steroid-5-alpha-reductase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1988-08-03 | — | — | EP | disclosed |
| US-4760071-A | Enzyme inhibitor | MERCK & CO., INC. (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0271219-A1 | Topical pharmaceutical composition containing 17-beta-methoxycarbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one | MERCK & CO. INC. (US) | 1988-06-15 | — | — | EP | disclosed |
| EP-0271219-A1 | Topical pharmaceutical composition containing 17-beta-methoxycarbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one | MERCK & CO. INC. (US) | 1988-06-15 | — | — | EP | disclosed |
| EP-0155096-A2 | 17 Beta-Substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1985-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129548-A1 | Polymorphs of an androgen receptor modulator | SHBG, AR, BRCA1 | AR 2/4885SRD5A2 36/4885KCNH2 4350/4885 |
| US-20090048283-A1 | Salt of an androgen receptor modulator | AR, SHBG, FSHR | AR 1/4885SRD5A2 42/4885KCNH2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.